NewsBite

Mesoblast Limited

ASX Announcements

Ryoncil Highlighted at Tandem Transplantation Meetings

Company Administration - Other

  • Feb 14, 2025
  • 3 pages

Change in substantial holding

Change in substantial holding

  • Feb 7, 2025
  • 5 pages

Market Sensitive

Ryoncil Commercial Launch Update and Product Pipeline

Progress Report

  • Jan 31, 2025
  • 5 pages

Market Sensitive

Quarterly Activities/Appendix 4C Cash Flow Report

CTE – Second Quarter Cashflow Report, CTE - Second Quarter Activity Report

  • Jan 31, 2025
  • 9 pages

Cleansing Notice

Cleansing Notice

  • Jan 24, 2025
  • 1 page

View all MSB announcements

December 2024

Mesoblast says its MSC cells will save childrens’ lives.

Mesoblast shares rocket on FDA approval, but CEO says risks remain

FDA approval for Mesoblast’s cell therapy used to treat children for complications that can occur during bone marrow transplants is a breakthrough for the biotech.

  • Michael Smith

July 2024

Melinda Snowden chairs the audit and risk committees at Megaport and Temple & Webster.

The secret to joining an ASX 200 board, from two women who succeeded

Eleven women were appointed to chair S&P/ASX 200 companies between March and June, taking the total to a record 25.

  • Sally Patten

February 2024

Atlassian’s Mike Cannon-Brookes and Scott Farquhar say they are prepared for the downturn.

What investors can learn from analysing R&D spending

High levels of R&D do not necessarily translate into increased returns on invested capital.

  • Tony Boyd

January 2024

In cases of hypoplastic left heart syndrome (HLHS), one side of the heart does not fully develop.

Mesoblast surges on FDA ‘rare paediatric disease’ designation

Shares in Australian biopharmaceutical company Mesoblast jumped 25 per cent after Revascor was recognised as a potential treatment for heart disease in babies.

  • Joanna Mather

August 2023

Mesoblast chief executive Silviu Itescu.

Mesoblast: the biotech that hasn’t – yet

After another knockback from the US regulator, its sceptics say it’s business as usual. And Mesoblast chief executive Silviu Itescu remains as optimistic as ever.

  • Jemima Whyte
Advertisement

July 2023

Pinnacle in its own right will bank $14.2 million in returns from principal investments.

Mesoblast and Neuren offer new parables for biotech investment

Neuren shares have gone parabolic after it developed a profit-spinning drug to treat Rett syndrome, while Mesoblast has an August 2 date with the FDA.

  • Tom Richardson

April 2023

Mesoblast rattles the tin for at least $37m, Bell Potter in tow

The biotech, which is developing treatments for cardiovascular disease and back pain, is no stranger to the capital markets. It went into a trading halt on Thursday.

  • Sarah Thompson, Kanika Sood and Emma Rapaport

December 2022

The ASX is trading lower this morning.

ASX drops 0.6pc; Star hits fresh lows

The S&P/ASX 200 Index declined in broad losses on the last trading session before Christmas, tracking a lacklustre session on Wall Street.

  • Cecile Lefort

June 2022

Shares in Mesoblast have plunged 85 per cent since August 2020.

Mesoblast accused of misleading investors

Mesoblast shares are down 85 per cent since August 2020, and its last reported net debt position of $US32.9 million means it needs to find funding sources.

  • Tom Richardson

February 2022

Bell Potter has shrugged off the departure of analysts in recent months.

Bell Potter shrugs off disappointing IPOs, analyst departures

The disastrous pandemic-era floats of Cleanspace and Laybuy have put pressure on the small-cap stock promotion industry.

  • Tom Richardson

December 2021

Silviu Itescu is chief executive and founder of Mesoblast.

Mesoblast shares tank as Novartis terminates deal

Questions have long been raised around a deal that was struck with the Swiss pharma company last year.

  • Carrie LaFrenz and Tom Richardson

September 2021

Mesoblast chief executive Silviu Itescu plans to meet with the US FDA in coming months.

Mesoblast says FDA has not put a ‘hold’ on drug trial

The biotech’s shares fell further on Wednesday as investor concerns increased over the delay in a trial for its key product.

  • Updated
  • Carrie LaFrenz

August 2021

Mesoblast CEO and founder, Silviu Itescu, is facing more questions from the FDA.

Mesoblast shares dive 16pc as FDA raises more questions

The biotech’s losses for the 2021 full year widened and it admitted that it will need more cash to keep running.

  • Carrie LaFrenz
Mesoblast chief executive Silviu Itescu just lost his CFO.

Mesoblast loses its CFO

Josh Muntner will leave on August 30 after 3½ years with the Melbourne-based biotech, but no reason was provided for his departure.

  • Carrie LaFrenz
Mesoblast chief executive Silviu Itescu has run the company since it listed on the ASX in 2004.

Ownership Matters tallies up Mesoblast cash outflows, raises

Get the marshmallows ready, the bonfire’s set to hit $1 billion at Mesoblast. 

  • Anthony Macdonald and Yolanda Redrup
Advertisement

July 2021

Mesoblast chief executive Silviu Itescu declined to answer emailed questions over the deal or a request for an interview.

Mesoblast boss won’t answer share deal questions

The biotech’s chief executive will not be fielding queries over a reconciliation gap of up to 27.7 million stocks in a previous contract.

  • Tom Richardson
Leslie Chong left a lucrative career with US biotechnology drug giant Genentech to run small Australian company Imugene.

Buy, hold, sell: Imugene, Liontown Mesoblast, Kogan, Dusk

The best and worst small-cap performers from FY21.

Silviu Itescu is chief executive and founder of Mesoblast, which is seeking to get approval for its drug to treat chronic lower back pain.

Mesoblast, Grünenthal downgrade partnership deal

The payments the Melbourne-based biotech will receive if certain milestones are met have been slashed by about $37.5 million.

  • Carrie LaFrenz

June 2021

The energy sector was once again the outstanding performer on the ASX, as oil prices continue their recent climb.

Energy stocks extend ASX’s record-breaking streak

Australian shares closed at another record high on Thursday supported by the energy sector and gains from all four major banks.

  • Alex Gluyas

May 2021

Mesoblast’s share price has declined 84 per cent from $4.54 on December 14 to $2.46 when trading closed last Thursday.

Mesoblast’s selective disclosure continues

The cash-burning biotech says its latest clinical data is a success, but it’s for a trial halted early as it was not expected to meet its endpoint.

  • Tom Richardson

Original URL: https://www.afr.com/company/msb-zp